Braxia Scientific treats depression, suicidality, and related mental health conditions.
Braxia is a company of tomorrow, focused on ketamine treatment and psychedelic medicine for advanced mental health treatments.
Why ketamine mental health treatment?
Ketamine is a safe and proven effective treatment for adults with depression, suicidality and related disorders. Ketamine is legally available administered under trained medical supervision. Braxia represents Best Practices in the implementation of ketamine in persons who are eligible.
Our Focus.
Addressable Market.
$8T
Global economic cost
Estimated cost to the global economy due to depressive disorders in U.S. dollars.
$238B
Estimated addressable market size
Estimated market size for anxiety disorder and depression treatments in U.S. dollars.
$16B
Annual U.S. Spend
Estimated annual expenditure in the United States on mental health treatments and ancillary services in U.S. dollars.
News Releases.
Braxia Scientific Reports Q3 2023 Financial Results and Provides Update on Acquisition Under LOI with Irwin Naturals
Braxia Health ketamine treatments up 29% YoY in Q3 2023 and revenue up 50.5% YoY TORONTO, ONTARIO Wednesday March 1, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the third quarter ended December 31, 2023. The Company also provided an update on the proposed acquisition of the Company by Irwin Naturals Inc. (CSE: IWIN) (OTCQB: IWINF) (FSE: 97X) ("Irwin") as outlined in the non-binding Letter of Intent ("LOI") announced January 27, 2023. Complete financial statements along with related management discussion and analysis and the LOI can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system...
Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement
TORONTO, ONTARIO February 27, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the “LIFE Offering”), resulting in the issuance of 13,658,524 units of the Company (each a “Unit”) at a price of $0.055 per Unit for aggregate proceeds of $751,218.83 (the “LIFE First Tranche”). Each Unit consists of one common share of the Company (each a “Common Share”) and one Common Share purchase warrant (each a “Warrant”). Each Warrant entitles its holder to purchase one additional Common Share at an exercise price of $0.07 for a period of 36 months from the date of issue....
Braxia Scientific Announces Offering up to $1.5 Million, Braxia Management to Participate in Concurrent Private Placement
TORONTO, ONTARIO February 7, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce an offering of up to 27,272,727 units of the Company (the “Units”) at a price of $0.055 per Unit for aggregate gross proceeds of up to $1,500,000.00 pursuant to the listed issuer financing exemption (the “LIFE Offering”) and a concurrent private placement of up to 7,272,727 Units (the “Placement Units”) for aggregate gross proceeds of up to $400,000 (the “Concurrent Placement”). Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of...
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and development Establishes large footprint of 17 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the US Combined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeutics TORONTO, ONTARIO January 27, 2023 – Braxia Scientific Corp. (“Braxia ”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce it has entered into a non-binding amended and restated letter of intent (“LOI”) for a business combination with Irwin Naturals Inc. (“Irwin”) (CSE: IWIN) (OTC: IWINF) (FRA: 97X). Irwin has been one...